Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Epilepsy – Current Treatment – Current Treatment: Physician Insights – Epilepsy (US)
For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…
Sickle Cell Disease | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2022
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to several…
Biomarkers in Oncology | Access & Reimbursement | US | Non-Small-Cell Lung Cancer, Breast Cancer, and Colorectal Cancer | 2022
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…
Parkinson’s Disease – Access & Reimbursement – Access & Reimbursement – Parkinson’s Disease (US)
Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of NHL comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key NHL patient populations covering 171 countries and more than 99% of…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Epidemiology – Middle East & Africa
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
